Skip to content

Effect of stellate ganglion block on vomiting, acute pain and chronic pain after thoracoscopic lobectomy

Effect of stellate ganglion block on vomiting, acute pain and chronic pain after thoracoscopic lobectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100215
Enrollment
Unknown
Registered
2025-04-05
Start date
2025-04-05
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vomiting and acute and chronic pain after thoracoscopic lobectomy

Interventions

Group SGB1:Stellate ganglion block was performed once before surgery
Group SGB2:Stellate ganglion block was performed before surgery and on the 2nd postoperative day
Group C:Without stellate ganglion block

Sponsors

The Second Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Collected from April 2025 ~ September 2026 The Second Affiliated Hospital of Fujian Medical University plans to undergo elective thoracoscopic lobectomy, ASA (American Society of Anesthesiologists) is graded as I~II, age 18~70 years old, normal communication, full understanding of the purpose and significance of this study, and willing to participate in this study Lung adenocarcinoma patients, the hospital ethics committee passed, signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic to local anesthetics; 2. Patients with Intraoperative freeze pathology ruled out lung adenocarcinoma or other lung diseases found during the operation; 3. Postoperative chemotherapy with neurotoxicity; 4. History of repeated operations; 5. Any medical condition that occurs during the study period that may put participant at risk for continuing the study; 6. Participants who could not complete the trial according to the provisions of the trial protocol (nerve block failure, follow-up failure, etc.).

Design outcomes

Primary

MeasureTime frame
Postoperative nausea and vomiting score;Postoperative VAS score;Incidence of postoperative chronic pain;Postoperative sleep quality score;P substance;Serotonin;ß-endorphins;Postoperative antiemetic drug dosage;

Secondary

MeasureTime frame
Sufentanil dosage;Remifentanil dosage;Number of effective compressions of the analgesic pump;Postoperative analgesics dosage;Vasoactive drug dosage;Operation time;Recovery time;

Countries

China

Contacts

Public ContactLihong Zhang

The Second Affiliated Hospital of Fujian Medical University

1100702024zhang@163.com+86 159 8592 8013

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026